Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction

Targeting of the PD-1/PD-L1 immunologic checkpoint is believed to have provided a real breakthrough in the field of cancer therapy in recent years. Due to the intrinsic limitations of antibodies, the discovery of small-molecule inhibitors blocking PD-1/PD-L1 interaction has gradually opened valuable...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fengling, Ye, Wenling, He, Yongxing, Zhong, Haiyang, Zhu, Yongchang, Han, Jianting, Gong, Xiaoqing, Tian, Yanan, Wang, Yuwei, Wang, Shuang, Ji, Shaoping, Liu, Huanxiang, Yao, Xiaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964281/
https://www.ncbi.nlm.nih.gov/pubmed/36835382
http://dx.doi.org/10.3390/ijms24043971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964281/
https://www.ncbi.nlm.nih.gov/pubmed/36835382
http://dx.doi.org/10.3390/ijms24043971

Ejemplares similares